Modality
Degrader
MOA
STINGag
Target
GLP-1R
Pathway
Notch
Wet AMDRett
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
Jun 2022
→ Jan 2029
Phase 1Current
NCT04707052
1,104 pts·Rett
2022-06→2029-01·Recruiting
1,104 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-232.8y awayInterim· Rett
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P1
Recruit…
Catalysts
Interim
2029-01-23 · 2.8y away
Rett
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04707052 | Phase 1 | Rett | Recruiting | 1104 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET |